Fortrea (FTRE) Stock Price, News & Analysis

Company Overview

Fortrea, Inc. is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services. Its small-molecule capabilities include custom synthesis, active pharmaceutical ingredient (API) production, and high-potency manufacturing. On the biologics side, the company offers cell line development, microbial and mammalian cell culture, purification, viral vector production, and fill-finish operations. Complementing these laboratory and production capacities, Fortrea delivers quality assurance, regulatory support, and supply chain management to help clients navigate stringent global regulatory environments.

With its headquarters in Horsham, Pennsylvania, Fortrea operates a network of facilities across North America, Europe, and Asia, serving a diverse international client base. These strategically located sites enable the company to provide flexible manufacturing scales—from gram-scale clinical batches to multi-metric-ton commercial volumes—while ensuring continuity of supply and localized regulatory compliance. Fortrea’s global footprint supports time-sensitive project needs and offers clients access to specialized technologies and expertise in multiple regions.

Led by Chief Executive Officer James Mullen, Fortrea’s leadership team draws on decades of experience in pharmaceutical development and manufacturing. The company’s executive management combines technical know-how with a customer-focused approach, aiming to foster long-term partnerships and drive innovation. As a newly independent entity, Fortrea continues to invest in capacity expansions and technology upgrades to meet the evolving demands of the life sciences industry.

Key Stats

• Today's Range: $14.64 to $15.61
• 50-Day Range: $8.87 to $15.64
• 52-Week Range: $3.97 to $18.67
• Volume: 565,587 shs
• Average Volume: 1.52 million shs
• Market Capitalization: $1.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.25
• Consensus Rating: Hold

Fortrea Stock Analysis - MarketRank™

Fortrea scored higher than 82% of companies evaluated by MarketBeat, and ranked 130th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Fortrea has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 5 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Fortrea has a consensus price target of $17.25, representing about 14.8% upside from its current price of $15.03.

Amount of Analyst Coverage

Fortrea has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 22.50%

Earnings Growth

Earnings for Fortrea are expected to grow by 22.50% in the coming year, from $0.80 to $0.98 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fortrea is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fortrea is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Fortrea has a PEG Ratio of 0.41. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Fortrea has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.07% of the float of Fortrea has been sold short.

Short Interest Ratio / Days to Cover

Fortrea has a short interest ratio ("days to cover") of 5.54.

Change versus previous month

Short interest in Fortrea has recently decreased by 10.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fortrea does not currently pay a dividend.

Dividend Growth

Fortrea does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.29

News Sentiment

Fortrea has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Fortrea this week, compared to 9 articles on an average week.

Search Interest

4 people have searched for FTRE on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fortrea insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,014.00 in company stock.

Percentage Held by Insiders

0.38% of the stock of Fortrea is held by insiders.

Percentage Held by Institutions

Fortrea has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/29/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:FTRE
• CIK: 1965040
• Web: www.fortrea.com
• Phone: 877-495-0816
• Fax: N/A
• Employees: 14,300
• Year Founded: 2023

Price Target and Rating

• Average Price Target for Fortrea: $17.25
• High Price Target: $25.00
• Low Price Target: $9.50
• Potential Upside/Downside: +11.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 19.41
• P/E Growth: 0.41
• Net Income: -$986.20 million
• Net Margins: -16.50%
• Pretax Margin: -16.51%
• Return on Equity: 9.51%
• Return on Assets: 1.96%

Debt

• Debt-to-Equity Ratio: 1.98
• Current Ratio: 0.95
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $2.72 billion
• Price / Sales: 0.54
• Cash Flow: $11.50 per share
• Price / Cash Flow: 1.35
• Book Value: $5.56 per share
• Price / Book: 2.79

Miscellaneous

• Outstanding Shares: 94,600,000
• Free Float: 94,241,000
• Market Cap: $1.47 billion
• Optionable: Optionable
• Beta: 1.92